The people this data actually matters for aren't talking about efficacy numbers 4/28/2026
Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.
View this post in the Community ā
Similar Community Posts Join
5 / 5 resultscommunity Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community New baldness drug boosts hair coverage by up to 86% in six months
A new extended-release oral minoxidil formulation claims to improve hair growth by maintaining steady blood levels, reducing side effects like hypotension, and potentially benefiting female hair loss. However, it is not considered groundbreaking as it builds on existing minoxidil treatments, and its effectiveness compared to current doses is debated.
community A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months.
VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.
community Iām taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
Related Research
6 / 6 results
research The Polycystic Ovary Syndrome - Challenges and Opportunities in Adolescent Medicine
Early treatment of PCOS in teens is crucial to prevent long-term health issues like diabetes and heart disease.
research The North American Menopause Society Recommendations for Clinical Care of Midlife Women
The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.
research Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.
research Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
This research highlights that engineered mice lacking the vitamin D receptor show multiple health issues similar to human vitamin D deficiency, underscoring the widespread impacts of the vitamin D endocrine system.
research Microemulsions as Carriers for Therapeutic Molecules
This review discusses various patent articles on microemulsion carriers in drug delivery systems and reports no new empirical findings.
research The acne hormones
This review discusses hormones that affect acne and highlights a statistically significant link between a low-glycemic-load diet and reduced acne activity, but reports no new experimental findings.